Maintenance Therapy For Copd Therapeutics
1. Modeyso patent expiration
Treatment: Method of treating adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an h3 k27m mutation with progressive disease following prior therapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12102639 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
| US10369154 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
| US10172862 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
| US9629842 | CHIMERIX | NA |
Apr, 2032
(6 years from now) | |
| USRE46290 | CHIMERIX | NA |
Apr, 2032
(6 years from now) | |
| US11976068 | CHIMERIX | NA |
Mar, 2036
(10 years from now) | |
| US9265765 | CHIMERIX | NA |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2030 |
Drugs and Companies using DORDAVIPRONE HYDROCHLORIDE ingredient
NCE-1 date: 06 August, 2029
Market Authorisation Date: 06 August, 2025
Dosage: CAPSULE
More Information on Dosage
MODEYSO family patents
